Not a single study
Story checked
Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study (opens in a new tab)
news-medical.net · 2026-10-09
Short answer
Not a single studyNo clear answer.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study
news-medical.net · 2026-10-09
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
This story isn't reporting one study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Open claim evidenceSearch result
No single source study.
The article covers a research area rather than reporting a specific new paper, so there is no single study to check it against.
Source layer
The paper behind the story
The source record for this check.
The research anchor for the report.
- Also referencedpresented as the new finding
https://oncopeptides.com/press-releases/oncopeptides-confirms-blood-brain-barrier-penetration-based-on-data-from-first-patients-in-glioblastoma-window-of-opportunity-study/
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedData from the first three treated patients demonstrate successful penetration of the human blood-brain barrier with intra-tumoral drug concentrations in line with preclinical models.View evidenceHide evidence
As statedfirst three treated patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedOncopeptides announces data from the first patients in its ongoing clinical Window-of-Opportunity study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma.View evidenceHide evidence
As statedfirst three treated patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedThe company says the findings provide a strong indication of a clinical proof-of-concept for the PDC platform’s mechanism in solid brain tumors.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedThe open-label INSULA study is being conducted at Oslo University Hospital in Norway in patients scheduled for surgery because of recurrent glioblastoma, using the EMA-approved drug melflufen from Oncopeptides’ PDC platform.View evidenceHide evidence
As statedtarget of approximately 10 patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedThe study’s primary objective in this part is to confirm blood-brain barrier penetration by analyzing active compound in resected tumor tissue after pre-surgery dosing.View evidenceHide evidence
As statedprimary endpoint in this part of the study
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedSafety and tolerability appear acceptable so far, with no major drug-related toxicity observed, no unexpected surgical complications, and the first treated patient having received five monthly doses without new tumor-related neurological symptoms.View evidenceHide evidence
As statedfive monthly doses
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedPatient recruitment will continue to about 10 patients to further characterize pharmacokinetics and pharmacodynamics.View evidenceHide evidence
As statedapproximately 10 patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Tumor-homing peptides in precision oncology.
Journal of Controlled Release : Official Journal of the Controlled Release Society · 2026 · PubMed
Dynamics of glioblastoma chemotherapy in blood–brain barrier
Chemoresistance in Glioblastoma · 2026 · Crossref
Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.
2026 · Europe PMC
Comment on "Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?".
Journal of Cancer Research and Clinical Oncology · 2026 · PubMed
Review for "Tuning Lipid Nanocarrier Mechanical Properties to improve Glioblastoma Targeting and Blood Brain Barrier Penetration"
2025 · Crossref
And 10 more candidates considered.